Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Current Signal: BUY (auto-tracking)
-6.40% $4.39
America/New_York / 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 57.01 mill |
EPS: | 0.850 |
P/E: | 5.16 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 12.99 mill |
Avg Daily Volume: | 0.213 mill |
RATING 2024-04-17 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Neutral | |
Return On Asset: | Buy | |
DE: | Buy | |
P/E: | Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 5.16 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0.11x |
Company: PE 5.16 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 3.98 - 4.80 ( +/- 9.27%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Tarriff Scott | Sell | 2 119 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Buy | 3 800 | Common Stock |
2024-02-27 | Cahill Brian Joseph | Sell | 1 589 | Common Stock |
2024-02-27 | Tarriff Scott | Buy | 12 950 | Common Stock |
2024-02-27 | Tarriff Scott | Sell | 3 154 | Common Stock |
INSIDER POWER |
---|
59.21 |
Last 99 transactions |
Buy: 818 589 | Sell: 362 958 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.39 (-6.40% ) |
Volume | 0.109 mill |
Avg. Vol. | 0.213 mill |
% of Avg. Vol | 51.22 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $5.21 | N/A | Active |
---|
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.